Dianthus Therapeutics Stock Today

DNTH Stock   23.25  0.38  1.61%   


10 of 100


Odds Of Distress

Less than 44

Below Average
Dianthus Therapeutics is trading at 23.25 as of the 21st of April 2024. This is a -1.61 percent down since the beginning of the trading day. The stock's open price was 23.63. Dianthus Therapeutics has about a 44 percent probability of financial distress in the next few years of operation but had a somewhat ok performance during the last 90 days. Dianthus Therapeutics symbol was changed from MGTA on 12th of September 2023. Equity ratings for Dianthus Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of May 2022 and ending today, the 21st of April 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of September 2023
Health Care
Dianthus Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 29.32 M outstanding shares of which 1.39 M shares are currently shorted by private and institutional investors with about 1.19 trading days to cover. More on Dianthus Therapeutics

Moving together with Dianthus Stock

  0.61MRK Merck Company Earnings Call This WeekPairCorr
  0.74OPT OptheaPairCorr
  0.87PBH Prestige Brand Holdings Financial Report 2nd of May 2024 PairCorr

Moving against Dianthus Stock

  0.56PCRX Pacira Pharmaceuticals Financial Report 1st of May 2024 PairCorr
  0.51EVO Evotec SE ADR Earnings Call This WeekPairCorr

Dianthus Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Dianthus Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Dianthus Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Older SymbolMGTA
CEO and PresidentidentMarino MBA
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Dianthus Therapeutics report their recommendations after researching Dianthus Therapeutics' financial statements, talking to executives and customers, or listening in on Dianthus Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Dianthus Therapeutics. The Dianthus consensus assessment is calculated by taking the average forecast from all of the analysts covering Dianthus Therapeutics.
Financial Strength
Based on the key indicators related to Dianthus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Dianthus Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Dianthus Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.0150.0158
Notably Down
Slightly volatile
Total Current LiabilitiesM9.6 M
Notably Down
Slightly volatile
Non Current Liabilities Total858.8 K904 K
Notably Down
Slightly volatile
Total Assets112.5 M179.4 M
Way Down
Slightly volatile
Total Current Assets107.1 M177.5 M
Way Down
Slightly volatile
Dianthus Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Dianthus Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dianthus Therapeutics' financial leverage. It provides some insight into what part of Dianthus Therapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Dianthus Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Dianthus Therapeutics deploys its capital and how much of that capital is borrowed.
Dianthus Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 585 K in liabilities. Debt can assist Dianthus Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Dianthus Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dianthus Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dianthus to invest in growth at high rates of return. When we think about Dianthus Therapeutics' use of debt, we should always consider it together with cash and equity.

Free Cash Flow

(38.82 Million)
Dianthus Therapeutics (DNTH) is traded on NASDAQ Exchange in USA. It is located in 7 Times Square, New York, NY, United States, 10036 and employs 53 people. Dianthus Therapeutics was previously known as Magenta Therapeutics and was traded on NASDAQ Exchange under the symbol MGTA. Dianthus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 524.21 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dianthus Therapeutics's market, we take the total number of its shares issued and multiply it by Dianthus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Dianthus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 29.32 M outstanding shares of which 1.39 M shares are currently shorted by private and institutional investors with about 1.19 trading days to cover. Dianthus Therapeutics generates negative cash flow from operations
Check Dianthus Therapeutics Probability Of Bankruptcy
Ownership Allocation
Dianthus Therapeutics retains a total of 29.32 Million outstanding shares. The majority of Dianthus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dianthus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dianthus Therapeutics. Please pay attention to any change in the institutional holdings of Dianthus Therapeutics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Dianthus Ownership Details

Dianthus Stock Price Odds Analysis

Coming from a normal probability distribution, the odds of Dianthus Therapeutics jumping above the current price in 90 days from now is about 55.41%. The Dianthus Therapeutics probability density function shows the probability of Dianthus Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.2188 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Dianthus Therapeutics will likely underperform. Moreover, dianthus Therapeutics has an alpha of 1.0462, implying that it can generate a 1.05 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 23.25HorizonTargetOdds Above 23.25
44.48%90 days
Based on a normal probability distribution, the odds of Dianthus Therapeutics to move above the current price in 90 days from now is about 55.41 (This Dianthus Therapeutics probability density function shows the probability of Dianthus Stock to fall within a particular range of prices over 90 days) .

Dianthus Therapeutics Historical Income Statement

Dianthus Therapeutics Income Statement is one of the three primary financial statements used for reporting Dianthus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Dianthus Therapeutics revenue and expense. Dianthus Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Dianthus Therapeutics' Research Development is increasing as compared to previous years. The Dianthus Therapeutics' current Gross Profit is estimated to increase to about 2.6 M, while Depreciation And Amortization is projected to decrease to under 337.2 K. View More Fundamentals

Dianthus Stock Against Markets

Picking the right benchmark for Dianthus Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Dianthus Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Dianthus Therapeutics is critical whether you are bullish or bearish towards Dianthus Therapeutics at a given time. Please also check how Dianthus Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Dianthus Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Efficient Frontier Now


Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Module

Dianthus Therapeutics Corporate Management

Elected by the shareholders, the Dianthus Therapeutics' board of directors comprises two types of representatives: Dianthus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dianthus. The board's role is to monitor Dianthus Therapeutics' management team and ensure that shareholders' interests are well served. Dianthus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dianthus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jennifer RuffVP AffairsProfile
Edward CarrChief OfficerProfile
Kristina MaximenkoChief OfficerProfile
MD MBAChief OfficerProfile
Adam EsqGeneral CounselProfile
Judson TaylorHead OperationsProfile

How to buy Dianthus Stock?

Before investing in Dianthus Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Dianthus Therapeutics. To buy Dianthus Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Dianthus Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Dianthus Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Dianthus Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Dianthus Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Dianthus Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

Already Invested in Dianthus Therapeutics?

The danger of trading Dianthus Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Dianthus Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Dianthus Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Dianthus Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Dianthus Stock analysis

When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Is Dianthus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.